BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Meet ‘NASA Mike,’ who’s done 105,000 handstands around the world - 2Ghassan Al-Duhaini to replace Abu Shabab as Popular Forces leader in Gaza
- 3Several killed in Ukraine and Russia after cross-border attacks
- 4Shelby County deputies charged with assault, placed on leave
- 5The Best Web-based Courses for Expertise Improvement
- Banks for High Fixed Store Rates: Augment Your Investment funds
- Embracing Practical Living and Ecological Protection
- Surprise! Saturn's huge moon Titan may not have a buried ocean after all
- 20-year-old who threatened German train attack remanded in custody
- 'Euphoria' releases Season 3 photos with Zendaya, Sydney Sweeney, Jacob Elordi and others: See them
- The Best Web-based Courses for Ability Advancement
- Congo declares its latest Ebola outbreak over, after 43 deaths
- The Red Sea strategy: What does Israel stand to gain from recognizing Somaliland?
- Step into Nature: A Survey of \Handling Trails with Solace\ Climbing Shoes
